Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate

Ramos-Quiroga, Josep Antoni; Bosch, Rosa; Castells, Xavier; Valero, Sergi; Nogueira, Mariana; Gómez, Núria; Yelmo, S.; Ferrer, Marc; Martínez, Yolanda V; Casas, Miguel

doi:10.2165/00023210-200822070-00005

Cited by 51 publications

(43 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15,19 A Spanish study based on chart reviews also found that a switch from MPH IR to MPH ER was associated with both a significant reduction of ADHD symptoms and longer treatment duration and compliance. 20 There is reason to believe that superiority in efficacy and more convenient medication of ER formulations may contribute to longer duration and better compliance. However, 2 recent meta-analyses have given conflicting results about the superiority in efficacy of ER formulations over IR formulations in controlled studies.…”

Section: Discussionmentioning

confidence: 99%

“…24,40 Central stimulant dosing seems to have been generally adequate (mean, 58.9 mg/d) and in line with other naturalistic and controlled studies of CS treatment in adults. 13,20,41 More than half of the patients tried 2 or more types of CS.…”

Section: Discussionmentioning

confidence: 99%

“…9,14 Few studies have investigated predictive factors for long CS treatment duration in adults, but some suggest there is an association between longer treatment duration and the use of extended-release (ER) formulations of CS. 15,19,20 Olfson and colleagues 15 also found that treatment by a psychiatrist was positively related to longer CS treatment duration. Mental health treatment in an emergency department during the 6 months before initiation of MPH treatment and younger age were related to shorter duration.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Predictive Factors for More Than 3 Years’ Duration of Central Stimulant Treatment in Adult Attention-Deficit/Hyperactivity Disorder

Torgersen¹,

Gjervan²,

Nordahl³

et al. 2012

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

There is effective short-term central stimulant (CS) treatment of attention-deficit/hyperactivity disorder (ADHD) symptoms in adult ADHD, and despite this, many patients discontinue the treatment too early. The present study examines the duration of CS treatment in a Norwegian cohort of adult ADHD to identify predictors for long treatment duration (≥ 3 years). The data were based on the medical records of a sample of 117 of all 119 adult ADHD patients diagnosed over a period of 8 years in a specific catchment area and treated with CS. A logistic regression model was applied to identify possible predictors for long treatment duration. The sample was severely impaired in terms of comorbidity, educational achievement, and employment. The median duration of CS treatment was 33.0 months. Use of extended-release formulations of methylphenidate predicted long treatment duration positively (odds ratio, 4.420 [95% CI, 1.875-10.419]), whereas baseline antisocial personality disorder predicted long treatment duration negatively (odds ratio, 0.210 [0.085-0.518]). This study showed that it is possible to treat severely impaired and highly comorbid adult ADHD patients with CS over years. The finding that extended-release formulations of methylphenidate predict long treatment duration supports previous research, and it is important to show this association in naturalistic samples such as in the present study. Comorbid antisocial personality disorder was a negative predictor of long CS treatment duration. Univariate analyses also indicate that comorbid substance use disorder is related to shorter duration of CS treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Predictive Factors for More Than 3 Years’ Duration of Central Stimulant Treatment in Adult Attention-Deficit/Hyperactivity Disorder

Torgersen¹,

Gjervan²,

Nordahl³

et al. 2012

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…A comparison of extended-versus immediate-release methylphenidate in adults suggested that adherence improved after switching to the long-acting formulation 31 ; similarly, treatment duration was found to be greater among children and adolescents who initiated treatment with extended-release methylphenidate versus those who used an immediate-release formulation 32 . A comparison of persistence with long-acting methylphenidate versus short-acting methylphenidate or mixed amphetamine salts likewise supports the notion that persistence is better with long-acting than with short-acting ADHD medications 33 .…”

Section: Discussionmentioning

confidence: 99%

Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population

Christensen

Sasané

Hodgkins

et al. 2010

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

Meta‐analysis of brain‐derived neurotrophic factor p.Val66Met in adult ADHD in four European populations

Sánchez-Mora

Ribasés

Ramos-Quiroga

et al. 2010

American J of Med Genetics Pt B

View full text Add to dashboard Cite

Attention-deficit hyperactivity disorder (ADHD) is a multifactorial, neurodevelopmental disorder that often persists into adolescence and adulthood and is characterized by inattention, hyperactivity and impulsiveness. Before the advent of the first genome-wide association studies in ADHD, genetic research had mainly focused on candidate genes related to the dopaminergic and serotoninergic systems, although several other genes had also been assessed. Pharmacological data, analysis of animal models and association studies suggest that Brain-Derived Neurotrophic Factor (BDNF) is also a strong candidate gene for ADHD. Several polymorphisms in BDNF have been reported and studied in psychiatric disorders but the most frequent is the p.Val66Met (rs6265G > A) single nucleotide polymorphism (SNP), with functional effects on the intracellular trafficking and secretion of the protein. To deal with the inconsistency raised among different case-control and family-based association studies regarding the p.Val66Met contribution to ADHD, we performed a meta-analysis of published as well as unpublished data from four different centers that are part of the International Multicentre Persistent ADHD CollaboraTion (IMpACT). A total of 1,445 adulthood ADHD patients and 2,247 sex-matched controls were available for the study. No association between the p.Val66Met polymorphism and ADHD was found in any of the four populations or in the pooled sample. The meta-analysis also showed that the overall gene effect for ADHD was not statistically significant when gender or comorbidity with mood disorders were considered. Despite the potential role of BDNF in ADHD, our data do not support the involvement of p.Val66Met in the pathogenesis of this neuropsychiatric disorder.

show abstract

Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate

Abstract: The switch from IR to OROS methylphenidate was associated with an improvement in both adherence and effectiveness. There were no differences between IR and OROS methylphenidate in terms of tolerability.

Cited by 51 publications

References 11 publications

Predictive Factors for More Than 3 Years’ Duration of Central Stimulant Treatment in Adult Attention-Deficit/Hyperactivity Disorder

Predictive Factors for More Than 3 Years’ Duration of Central Stimulant Treatment in Adult Attention-Deficit/Hyperactivity Disorder

Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population

Meta‐analysis of brain‐derived neurotrophic factor p.Val66Met in adult ADHD in four European populations

Contact Info

Product

Resources

About